GSK HIV drug poses no increased heart attack risk, FDA says
GlaxoSmithKline’s HIV drug abacavir does not increase the risk of a heart attack, according to results of a new safety review by the U.S. Food and Drug Administration. The FDA issued an alert in 2008 after serious and sometimes fatal reactions were associated with the drug.